<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of HIV-2 infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of HIV-2 infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of HIV-2 infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geoffrey S Gottlieb, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John A Bartlett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2193841">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in West Africa, where it is endemic [
         <a href="#rid1">
          1
         </a>
         ]. HIV-2 infection is also found in areas with cultural and socio-economic ties to West Africa, including the United States. Although multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1, the majority of people living with HIV-2 will eventually have disease progression, and mortality rates among persons with HIV-1 and HIV-2 who have advanced disease appear similar when adjusting for CD4 cell count, age, and sex [
         <a href="#rid1">
          1-16
         </a>
         ]. Thus, antiretroviral therapy plays an important role in patient management.
        </p>
        <p>
         This topic will address the approach to treatment in persons with HIV-2 infection. The epidemiology, natural history, clinical manifestations, and diagnosis of HIV-2 infection are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13966.html" rel="external">
          "Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16727.html" rel="external">
          "Clinical manifestations and diagnosis of HIV-2 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3252143233">
         <span class="h1">
          GOALS OF THERAPY FOR HIV-2 INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with HIV-1 infection, the following benchmarks are critical goals of antiretroviral therapy (ART) [
         <a href="#rid17">
          17,18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced morbidity and mortality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement in quality of life
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Durable suppression of HIV-2 viral load
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restoration of immune function (as indicated by CD4 cell count)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of HIV-2 transmission to uninfected sex or needle sharing partners
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of mother to child transmission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of drug resistance
        </p>
        <p>
        </p>
        <p>
         However, there are scant data on HIV-2 infection related to these basic principles. For example, the selection of ART for patients with HIV-2 is complicated by the absence of published randomized clinical trial data. Routine HIV-2 viral load testing is available in the United States at the University of Washington [
         <a href="#rid19">
          19
         </a>
         ] and the New York State Department of Health [
         <a href="#rid20">
          20
         </a>
         ]. However, drug resistance assays for HIV-2, which are considered key to the management of HIV-1 infection, are mainly relegated to research laboratories [
         <a href="#rid18">
          18
         </a>
         ]. It is also unknown as to whether treatment-induced viral suppression of HIV-2 is associated with decreased transmission. (See
         <a class="medical medical_review" href="/z/d/html/13966.html" rel="external">
          "Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection", section on 'Risk of transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2194364">
         <span class="h1">
          INDICATORS OF IMMUNE FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CD4 cell count is the main indicator of immune function in patients who are infected with HIV-1 or HIV-2, and is a strong predictor of disease progression and survival [
         <a href="#rid18">
          18,21,22
         </a>
         ]. Although patients with HIV-2 infection tend to have a slower immunologic decline than those with HIV-1, once the CD4 cell count is &lt;200 cells/microL, patients with HIV-2 are also at risk for morbidity and mortality related to opportunistic infections [
         <a href="#rid1">
          1-16
         </a>
         ]. Interestingly, levels of viremia in patients with HIV-2 tend to be much lower than those seen with HIV-1 infection, even at stages of advanced immunosuppression [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13966.html" rel="external">
          "Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection", section on 'Lower levels of viremia'
         </a>
         .)
        </p>
        <p>
         In patients with HIV-1 infection, it has been well-established that untreated patients with a CD4 count &lt;200 cells/microL are at high risk for opportunistic infections and mortality. Guidelines by the United States Department of Health and Human Services [
         <a href="#rid18">
          18
         </a>
         ], and the World Health Organization [
         <a href="#rid24">
          24
         </a>
         ], recommend starting antiretroviral therapy (ART) irrespective of CD4 cell count to reduce the risk of serious AIDS- and non-AIDS-related complications. The CD4 cell count is used to guide whether to initiate chemoprophylaxis to prevent opportunistic infections. Discussions of when to initiate ART in patients with HIV-2 and the use of chemoprophylaxis to prevent opportunistic infections are found below. (See
         <a class="local">
          'When to start antiretroviral therapy'
         </a>
         below and
         <a class="local">
          'Prevention and treatment of opportunistic infections'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2193865">
         <span class="h1">
          CLASSES OF ANTIRETROVIRAL MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are multiple classes of antiretroviral medications for the treatment of HIV-1 including  (
         <a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
         However, there are no antiretroviral medications approved by the US Food and Drug Administrations for the treatment of HIV-2. In addition, HIV-2 has intrinsic resistance to certain classes of antiretroviral medications (ie, NNRTIs, fusion inhibitors), while within other classes (eg, PIs), not all agents are considered equally potent. (See
         <a class="local">
          'Nonnucleoside reverse transcriptase inhibitors'
         </a>
         below and
         <a class="local">
          'Fusion inhibitors'
         </a>
         below and
         <a class="local">
          'Protease inhibitors'
         </a>
         below.)
        </p>
        <p>
         Our approach to antiretroviral therapy for patients with HIV-2 infection is described below. (See
         <a class="local">
          'Selection of an initial antiretroviral regimen'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H989621">
         <span class="h1">
          HIV-2 DRUG RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug resistance data are important in guiding the selection of antiretroviral therapy regimens. Generally speaking, HIV drug resistance occurs when viral replication continues in the face of ongoing drug pressure. However, there are some important differences between HIV-1 and HIV-2 in terms of drug resistance patterns [
         <a href="#rid25">
          25,26
         </a>
         ]. Much of the data below has emerged from specialized research laboratories; commercial HIV-2 drug resistance testing is not clinically available. Basic concepts and principles regarding HIV drug resistance are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2195002">
         <span class="h2">
          Nucleoside reverse transcriptase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most data indicate that HIV-1 and HIV-2 are equally susceptible to all nucleoside reverse transcriptase inhibitors (NRTIs) currently in clinical use [
         <a href="#rid27">
          27-33
         </a>
         ]. However, resistance data suggest that tenofovir (or
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         ) may be favored as a first-line agent over
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         , when available [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Assays for drug resistance testing'
         </a>
         below.)
        </p>
        <p>
         Drug resistance is prevalent in treatment-experienced patients with virologic failure. Commonly seen mutations include those that confer high-level resistance to
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         /
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         (eg, M184V) and most NRTIs (eg, Q151M pathway) [
         <a href="#rid34">
          34,35
         </a>
         ]. In vitro data suggest that as few as two NRTI mutations in HIV-2 (eg, Q151M and M184V) can confer full resistance to
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         and lamivudine [
         <a href="#rid33">
          33,36
         </a>
         ].
        </p>
        <p>
         In contrast, tenofovir and
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         may maintain partial activity in the presence of mutations known to confer decreased susceptibility to other NRTIs (eg, K65R or Q151M alone or together); however, class-wide nucleoside resistance is demonstrated when all three major NRTI mutations are present (ie, K65R, Q151M and M184V) [
         <a href="#rid33">
          33,37,38
         </a>
         ].
        </p>
        <p>
         Drug resistance data also suggest some important differences between HIV-1 and HIV-2:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients failing thymidine analogues (eg,
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         or
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         ) often do not have the expected thymidine analog mutations (TAMs) associated with the use of these drugs; this suggests that alternative resistance pathways may exist for HIV-2 compared with HIV-1 [
         <a href="#rid34">
          34,39-42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some NRTI mutations are selected more frequently in patients with HIV-2 compared with those with HIV-1 (eg, K65R or Q151M) [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two key NRTI thymidine analog mutations (TAMS) (M41L and T215Y), which have a negative impact on HIV-1 drug susceptibility to NRTIs, appear to have no effect on HIV-2 susceptibility to
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Detailed information on thymidine analog mutations is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing", section on 'Nucleoside reverse transcriptase inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2196338">
         <span class="h2">
          Protease inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The protease inhibitor (PI) class has variable activity against HIV-2. PIs with the greatest in vitro activity include: lopinavir,
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9877" href="/z/d/drug information/9877.html" rel="external">
          saquinavir
         </a>
         [
         <a href="#rid18">
          18,43-45
         </a>
         ]. Drug susceptibility data suggest that
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         , amprenavir,
         <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">
          indinavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">
          nelfinavir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">
          tipranavir
         </a>
         have lower potency against HIV-2 isolates compared with HIV-1, and should be avoided [
         <a href="#rid27">
          27,43-48
         </a>
         ].
        </p>
        <p>
         The HIV-2 protease contains natural polymorphisms that are commonly associated with HIV-1 drug resistance, including major mutations (eg, V32I/L, M46I/V, I47V) and minor mutations (eg, L10VI, E35G/R, Q58E, A71V/I, G73A/T) [
         <a href="#rid26">
          26,34,37,46,47,49-53
         </a>
         ]. These mutations are the likely reason for variable PI potency against HIV-2 [
         <a href="#rid54">
          54
         </a>
         ]; in addition, these mutations may increase the risk of virologic failure in patients with HIV-2 during PI-based ART [
         <a href="#rid39">
          39,53,55
         </a>
         ]. Detailed information on PI drug resistance mutation is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing", section on 'Protease inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2196498">
         <span class="h2">
          Integrase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In
         <em>
         </em>
         vitro data suggest that integrase inhibitors (
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , bictegravir, and
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          cabotegravir
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ]) have potent anti-HIV-2 activity [
         <a href="#rid57">
          57-64
         </a>
         ]. Studies that have evaluated genotypic resistance among integrase inhibitor-naive patients with HIV-2 infection found no key mutations associated with resistance to integrase inhibitors at the pre-treatment baseline [
         <a href="#rid58">
          58,65
         </a>
         ].
        </p>
        <p>
         However, similar to HIV-1, the development of integrase inhibitor resistance during ART is a concern for HIV-2 infection [
         <a href="#rid48">
          48,66
         </a>
         ]. In one small study of patients with HIV-2, virologic failure during raltegravir-containing combination ART was associated with the emergence of key signature mutations that confer
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         resistance [
         <a href="#rid67">
          67
         </a>
         ]. Additionally, the key HIV-1 integrase inhibitor resistance mutations, Q148R and N155H, confer resistance to HIV-2 [
         <a href="#rid59">
          59,67
         </a>
         ]. Although another key integrase inhibitor mutation, Y143C, does not confer significant resistance to HIV-2 by itself, it can cause resistance in conjunction with ancillary mutations [
         <a href="#rid62">
          62,64
         </a>
         ]. Emerging data also demonstrate that the integrase inhibitor resistance mutations G118R and 231ins (5 amino acid insert at IN codon 231) confer resistance to first and second generation INSTIs [
         <a href="#rid68">
          68,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing", section on 'Factors contributing to resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing", section on 'Integrase strand transfer inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2196646">
         <span class="h2">
          CCR5 coreceptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         CCR5 coreceptor antagonists are effective against HIV-1 strains, which use the CCR5 coreceptor for cell entry. In vitro data and anecdotal reports suggest that CCR5 antagonists, such as
         <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">
          maraviroc
         </a>
         , may also be effective against HIV-2 as well [
         <a href="#rid70">
          70-73
         </a>
         ]. However, the clinical effectiveness of this drug class remains uncertain since HIV-2 may use other co-receptors for cellular entry (eg, CXCR4, CCR1, CCR2b, CCR3, CXCR6 and GPR15) with greater affinity than HIV-1 [
         <a href="#rid74">
          74-76
         </a>
         ]. Furthermore, the susceptibility of CCR5-tropic isolates from patients with HIV-2 and AIDS was lower than isolates from asymptomatic patients [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">
          "Interpretation of HIV drug resistance testing", section on 'CCR5 antagonists'
         </a>
         .)
        </p>
        <p>
         Viral tropism assays to determine treatment candidacy for CCR5 inhibitors are not routinely available for clinical care, but assays for HIV-2 infection are being evaluated [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2195182">
         <span class="h2">
          Nonnucleoside reverse transcriptase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV-2 is intrinsically resistant to nonnucleoside reverse transcriptase inhibitors (NNRTIs), including second generation drugs, such as
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         , and
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         [
         <a href="#rid79">
          79,80
         </a>
         ]. Thus, this drug class should not be used in HIV-2 therapy and should be avoided in dual HIV-1/HIV-2 infection as well [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H356294">
         <span class="h2">
          Fusion inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV-2 is intrinsically resistant to
         <a class="drug drug_general" data-topicid="8609" href="/z/d/drug information/8609.html" rel="external">
          enfuvirtide
         </a>
         and should not be used for treatment of patients with HIV-2 or dual infection [
         <a href="#rid27">
          27,83,84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1758168404">
         <span class="h2">
          Attachment inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest HIV-2 is resistant to the attachment inhibitor
         <a class="drug drug_general" data-topicid="128916" href="/z/d/drug information/128916.html" rel="external">
          fostemsavir
         </a>
         [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H669300150">
         <span class="h2">
          Post-attachment inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited in-vitro data suggests the post-attachment inhibitor,
         <a class="drug drug_general" data-topicid="117178" href="/z/d/drug information/117178.html" rel="external">
          Ibalizumab
         </a>
         , inhibits HIV-2 replication [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H428094073">
         <span class="h2">
          Capsid inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited in vitro data suggest the capsid inhibitor,
         <a class="drug drug_general" data-topicid="140392" href="/z/d/drug information/140392.html" rel="external">
          lenacapavir
         </a>
         , has activity against HIV-2 but is reduced compared to HIV-1 [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1542629462">
         <span class="h2">
          Investigational drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited in vitro data suggest the investigational nucleoside reverse transcriptase translocation inhibitor, islatravir (MK-8591, EFdA), has more potent activity against HIV-2 than HIV-1 [
         <a href="#rid88">
          88
         </a>
         ]. By contrast, in vitro data suggest that HIV-2 is intrinsically resistant to maturation inhibitors, which are in development [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H357199">
         <span class="h1">
          WHEN TO START ANTIRETROVIRAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no data regarding the optimal time to initiate antiretroviral therapy (ART) in HIV-2 infection, and guideline panels vary in their recommendations [
         <a href="#rid18">
          18,82,90-92
         </a>
         ]. It is helpful to examine benchmarks for HIV-1 infection and how they may apply to HIV-2 infection.
        </p>
        <p class="headingAnchor" id="H183744">
         <span class="h2">
          HIV-1 infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         ART should be initiated in patients with HIV-1 infection, regardless of CD4 cell count. A detailed discussion of when to initiate ART is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13980.html" rel="external">
          "Use and impact of antiretroviral therapy for HIV infection in resource-limited settings", section on 'Initiation of ART'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H183751">
         <span class="h2">
          HIV-2 infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with HIV-1/HIV-2 dual infection should initiate antiretroviral therapy. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p>
         In addition, we recommend initiating ART in patients with HIV-2 monoinfection who:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have an AIDS defining illness (see
         <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">
          "The natural history and clinical features of HIV infection in adults and adolescents", section on 'AIDS-defining conditions'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          OR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have a comorbid condition that may benefit from ART (eg, HIV-associated nephropathy and neurocognitive disorders, thrombocytopenia, chronic hepatitis B virus infection) (see
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6679.html" rel="external">
          "HIV-associated cytopenias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98405.html" rel="external">
          "HIV-associated neurocognitive disorders: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">
          "Treatment of chronic hepatitis B in patients with HIV"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          OR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are pregnant (see
         <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">
          "Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">
          "Prevention of vertical HIV transmission in resource-limited settings"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          OR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are in a discordant sexual partnership with an HIV-2-negative individual or share needles with an injection partner who is HIV-2-negative.
        </p>
        <p>
        </p>
        <p>
         We also suggest initiating ART in patients who have:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A CD4 cell count below normal (ie, less than approximately 750 copies/microL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          OR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A detectable plasma HIV-2 RNA (see
         <a class="medical medical_review" href="/z/d/html/16727.html" rel="external">
          "Clinical manifestations and diagnosis of HIV-2 infection", section on 'Testing for HIV-2 infection'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         A shared decision-making approach should be used when deciding to start ART in asymptomatic patients with HIV-2 who have a normal CD4 cell count
         <strong>
          and
         </strong>
         an undetectable HIV-2 viral load. Many patients with HIV-2 who have an undetectable HIV-2 viral load and a normal CD4 count may never progress to AIDS or death [
         <a href="#rid16">
          16,93-95
         </a>
         ]. Thus, the risks of taking ART must be weighed against the unknown benefits of improving clinical outcomes and preventing HIV-2 transmission.
        </p>
        <p class="headingAnchor" id="H354169">
         <span class="h1">
          CLINICAL DATA ON ANTIRETROVIRAL THERAPY OF HIV-2
         </span>
        </p>
        <p class="headingAnchor" id="H11422537">
         <span class="h2">
          Importance of viral suppression
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are conflicting data as to whether immune recovery (as measured by increases in CD4 cell counts), in response to antiretroviral therapy (ART), is as robust in HIV-2 as in HIV-1 infection [
         <a href="#rid35">
          35,39,93,94,96,97
         </a>
         ]. However, among patients who attain viral suppression on ART, significant increases in CD4 counts are usually observed [
         <a href="#rid96">
          96,98
         </a>
         ]. Viral suppression is also associated with a decreased risk of drug resistance [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H354448">
         <span class="h2">
          HIV-2 monoinfection
         </span>
        </p>
        <p class="headingAnchor" id="H11422492">
         <span class="h3">
          Observational data
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in HIV-1 treatment, the majority of studies have utilized three-drug combination regimens. Observational studies for the treatment of HIV-2 have mainly included
         <a class="drug drug_general" data-topicid="10221" href="/z/d/drug information/10221.html" rel="external">
          zidovudine-lamivudine
         </a>
         in combination with the ritonavir-boosted protease inhibitor, lopinavir [
         <a href="#rid99">
          99
         </a>
         ]. Subsequent studies from West Africa have included tenofovir disoproxil fumarate-lamivudine plus lopinavir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         as the primary regimen [
         <a href="#rid100">
          100
         </a>
         ]. Antiretroviral medications were often chosen based on restricted availability in locales within West Africa, where many of these studies were performed [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p>
         The largest study to date included 422 patients with HIV-2 infection from West Africa [
         <a href="#rid103">
          103
         </a>
         ]. Those treated with a boosted protease inhibitor (PI)-based regimen (which was typically
         <a class="drug drug_general" data-topicid="10221" href="/z/d/drug information/10221.html" rel="external">
          zidovudine-lamivudine
         </a>
         plus ritonavir-boosted lopinavir) had significantly higher increases in CD4 count compared with those treated with a triple NRTI regimen, or an unboosted PI-based regimen (191, 110, and 133 cells/microL, respectively). In this study, viral load data was generally not available.
        </p>
        <p>
         Another large study from Senegal followed 291 participants for 926 person-years of follow-up over 13 years; most were treated with tenofovir disoproxil fumarate-lamivudine plus lopinavir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         starting in 2014 [
         <a href="#rid100">
          100
         </a>
         ]. Over the study period, 76.7 percent of plasma viral loads were suppressed in patients receiving ART, and the median CD4 cell count gain during the first two years on study was 84 cells/microL.
        </p>
        <p>
         Three smaller case series from Europe (76 patients), France (29 patients), and the Gambia (45 patients) also support the effectiveness of lopinavir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         as part of combination ART [
         <a href="#rid23">
          23,96,99
         </a>
         ]. Within these cohort studies, ART led to viral suppression in the majority of patients with significant improvements in CD4 cell counts.
        </p>
        <p>
         There is little clinical data on the use of other HIV-2 "active" PIs, such as
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         . However, available data suggest that protease inhibitors should be given with low-dose
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         (or
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ) to boost serum levels of the parent drug (eg "pharmacokinetic boosting"). As an example, use of unboosted
         <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">
          indinavir
         </a>
         or
         <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">
          nelfinavir
         </a>
         was associated with high rates of virologic failure [
         <a href="#rid34">
          34,35
         </a>
         ] and multiclass drug resistance [
         <a href="#rid34">
          34
         </a>
         ], while ritonavir-boosted indinavir was associated with high rates of viral suppression in one small cohort [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'
         </a>
         .)
        </p>
        <p>
         Scant data are available on the use of other antiretroviral combinations. Similar to patients with HIV-1, triple NRTI regimens are inferior to PI-based regimens in HIV-2 treated patients [
         <a href="#rid99">
          99,103
         </a>
         ]. By contrast, an increasing number of reports suggest that integrase inhibitors are clinically effective [
         <a href="#rid57">
          57,58,104-106
         </a>
         ]. (See
         <a class="local">
          'Integrase inhibitors'
         </a>
         above.)
        </p>
        <p>
         Only a few studies have looked at the efficacy of second-line or salvage regimens for HIV-2 infection. These regimens mainly used combinations that included boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         and
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ; however, outcomes were generally suboptimal [
         <a href="#rid107">
          107-109
         </a>
         ]. Thus, consultation with an HIV-2 expert is warranted when determining treatment options in the patient with virologic failure on antiretroviral therapy.
        </p>
        <p class="headingAnchor" id="H2540227432">
         <span class="h3">
          Clinical trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Published data from 30 patients enrolled in a trial evaluating a single-tablet regimen of
         <a class="drug drug_general" data-topicid="86285" href="/z/d/drug information/86285.html" rel="external">
          elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate
         </a>
         showed 28 of 30 patients had viral suppression/maintenance of control at 48 weeks (modified intention to treat), and the median increase in CD4 count was approximately 161 cells/microL [
         <a href="#rid98">
          98
         </a>
         ]. One individual developed virologic failure and had multidrug-resistant HIV-2 (reverse transcriptase mutation K65R, integrase mutations G140S and Q148R) detected at week 48. Another pilot trial evaluating 30 patients with HIV-2 who received
         <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">
          tenofovir disoproxil fumarate-emtricitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         demonstrated a median CD4 count increase of 87 cells/microL, and 27 of 28 patients had a viral load of &lt;40 copies/mL at 48 weeks [
         <a href="#rid110">
          110
         </a>
         ]. The one individual with virologic failure had integrase inhibitor resistance mutations (E92Q, T97A, and Y143CGHR).
        </p>
        <p>
         Several other clinical trials in ART-naïve patients have completed enrolment and are awaiting results; these include a trial comparing
         <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">
          tenofovir disoproxil fumarate-emtricitabine
         </a>
         with either
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         or lopinavir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         , as well as an open-label, single-arm trial of
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         combined with either tenofovir disoproxil fumarate-emtricitabine or
         <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">
          abacavir-lamivudine
         </a>
         [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H354176">
         <span class="h2">
          HIV-1 and HIV-2 dual infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The only data on ART for HIV-1/HIV-2 dual infection is based on a few case reports and case series; outcomes were poor, immunologic and virologic failure rates were high, and ARV resistance (usually related to HIV-2) was common [
         <a href="#rid55">
          55,113-116
         </a>
         ]. Consultation with an HIV-2 expert is warranted for dually-infected patients.
        </p>
        <p class="headingAnchor" id="H11422608">
         <span class="h1">
          ASSAYS FOR DRUG RESISTANCE TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HIV-1 infection, drug resistance testing is recommended at initial diagnosis, to assess for transmitted drug resistance (TDR), and at virologic failure, to assess for acquired drug resistance. (See
         <a class="medical medical_review" href="/z/d/html/3769.html" rel="external">
          "Overview of HIV drug resistance testing assays"
         </a>
         .)
        </p>
        <p>
         A similar approach to testing is desirable for persons with HIV-2. However, drug resistance testing assays are not commercially available for HIV-2 infection, which hampers the ability to select the optimal medication regimen for treatment initiation or modification. Fortunately, transmitted drug resistance has rarely been reported in HIV-2 infection [
         <a href="#rid117">
          117-120
         </a>
         ]. However, virologic failure in an patient with HIV-2 on ART is associated with acquired drug resistance that affects multiple classes of drugs [
         <a href="#rid34">
          34,42,121
         </a>
         ].
        </p>
        <p>
         Drug resistance testing may be obtained from research facilities such as the University of Washington (contact Dr. Geoffrey Gottlieb,
         <a class="__cf_email__" data-cfemail="24434b5050484d41466451530a414051" href="/cdn-cgi/l/email-protection">
          [email protected]
         </a>
         ).
        </p>
        <p>
         Interpretation of HIV-2 drug resistance genotyping can be obtained using the Stanford University HIV-2 Drug Resistance Database [
         <a href="#rid26">
          26
         </a>
         ] or the European Union HIV-2 GRADE Drug Resistance Database [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2193896">
         <span class="h1">
          SELECTION OF AN INITIAL ANTIRETROVIRAL REGIMEN
         </span>
        </p>
        <p class="headingAnchor" id="H2196659">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, there are no published randomized clinical trials evaluating the selection of antiretroviral medications for persons with HIV-2 infection, so the optimal strategy has not yet been defined. Guidance on antiretroviral selection for patients with HIV-2 largely depends upon in vitro drug susceptibility data from research laboratories and observational data from cohort studies and small single-arm trials. (See
         <a class="local">
          'HIV-2 drug resistance'
         </a>
         above and
         <a class="local">
          'HIV-2 monoinfection'
         </a>
         above.)
        </p>
        <p>
         Until further data are available, two nucleoside reverse transcriptase inhibitors (NRTIs) should form the backbone of therapy and should be used in combination with a third agent from a different class, similar to the treatment of HIV-1. However, in contrast to HIV-1, the third drug should
         <strong>
          not
         </strong>
         include any agent from the nonnucleoside reverse transcriptase (NNRTI) class since HIV-2 is intrinsically resistant to these medications. Instead, an integrase strand transfer inhibitor (eg,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or bictegravir), or alternatively, an HIV-2 active boosted protease inhibitor (eg, lopinavir,
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         ), should be used.
        </p>
        <p>
         Simplicity (pill burden and dosing schedule) of the ART regimen is likely to improve adherence and reduce the risk of virologic failure. Thus, a single-tablet regimen is preferred, when possible. However, there are no data on using a two-drug regimen with an integrase inhibitor backbone (eg,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         ) for HIV-2 infection, and pending additional data these two drug regimens should not be used.
        </p>
        <p class="headingAnchor" id="H25068806">
         <span class="h2">
          Preferred regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon available in vitro and observational data, several antiretroviral regimens can be used for the treatment of HIV-2 infection. (See
         <a class="local">
          'Clinical data on antiretroviral therapy of HIV-2'
         </a>
         above.)
        </p>
        <p>
         We suggest a nucleoside combination (
         <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">
          tenofovir disoproxil fumarate-emtricitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">
          tenofovir alafenamide-emtricitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">
          abacavir-lamivudine
         </a>
         ) be used with an integrase strand transfer inhibitor (
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         /
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or bictegravir). An alternative option is to use a nucleoside combination with a boosted protease inhibitor (ritonavir-boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         , ritonavir-boosted lopinavir). (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
         Single-tablet INSTI-based regimens for HIV-2 include abacavir-lamivudine-dolutegravir,
         <a class="drug drug_general" data-topicid="86285" href="/z/d/drug information/86285.html" rel="external">
          elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate
         </a>
         ,
         <a class="drug drug_general" data-topicid="105353" href="/z/d/drug information/105353.html" rel="external">
          elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">
          bictegravir-emtricitabine-tenofovir alafenamide
         </a>
         . Coformulated
         <a class="drug drug_general" data-topicid="118518" href="/z/d/drug information/118518.html" rel="external">
          darunavir-cobicistat-emtricitabine-tenofovir alafenamide
         </a>
         is available as a single-tablet protease inhibitor-based regimen.
        </p>
        <p>
         If an
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         regimen is being considered, patients must first be tested for the presence of HLA-B*57:01. Abacavir is
         <strong>
          contraindicated
         </strong>
         in patients who are HLA-B*57:01-positive. (See
         <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">
          "Abacavir hypersensitivity reaction"
         </a>
         .)
        </p>
        <p>
         The choice of regimen also depends upon the presence or absence of comorbid conditions (eg, reduced kidney function, hepatitis B virus infection), desire to become pregnant, and potential drug-drug interactions. More detailed discussions of how to select a regimen in women and patients with comorbid conditions are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Additional considerations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2193904">
         <span class="h1">
          PATIENT MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H353902">
         <span class="h2">
          HIV RNA assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         Viral load testing should be used to monitor response to therapy in patients with HIV-1, HIV-2, or with dual infection. A discussion of viral load monitoring during antiretroviral therapy (ART) is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy"
         </a>
         .)
        </p>
        <p>
         However, unlike HIV-1, the availability of HIV-2 RNA testing is quite limited. It can be obtained from the following laboratories [
         <a href="#rid19">
          19,20,123,124
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States contact:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         University of Washington Lab Medicine Community Services: (phone 1-800-713-5198 or
         <a class="__cf_email__" data-cfemail="89eae6e4e4faecfbffc9fca7fee8fae1e0e7eefde6e7a7ecedfc" href="/cdn-cgi/l/email-protection">
          [email protected]
         </a>
         )
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdlmp.uw.edu%2Fsite%2Fcontact&amp;token=zpNCX14A2R12bA0oIWem49nKG4OC3fUFqGl9yj7iUjaCbBrNdkjod6HUzp5MDIeJ&amp;TOPIC_ID=16252" target="_blank">
          https://dlmp.uw.edu/site/contact
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New York State Dept. of Health Lab: (phone 518-473-6007)
        </p>
        <p class="bulletIndent1">
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.wadsworth.org%2Fprograms%2Fid%2Fbloodborne-viruses%2Fclinical-testing%2Fhiv-2-nucleic-acid&amp;token=maHMlRbuVtQiq5YNS9JBc371l1wgDb%2FKyPPP8di7y0zHIP35XPBxLbDheW1p862UzpXwUcjslnL66%2FhCiXOo7%2FRGKRdRuR%2BCWFh8X4jJ3a%2FILOHzfjCA3qHJurdogkys&amp;TOPIC_ID=16252" target="_blank">
          http://www.wadsworth.org/programs/id/bloodborne-viruses/clinical-testing/hiv-2-nucleic-acid
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Europe, contacts are available at
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fetudes.isped.u-bordeaux2.fr%2Fachiev2e&amp;token=%2B6GpdMdGVV7XJNn9uS0vJTn04OIuBn9H36m9%2B5woNQDPDb9VcWoGtyt6QkHTq30eF5NvKM20d%2Bk7gokHAla%2Fmg%3D%3D&amp;TOPIC_ID=16252" target="_blank">
          http://etudes.isped.u-bordeaux2.fr/achiev2e
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H353953">
         <span class="h2">
          CD4 cell counts and clinical monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of these basic tools for monitoring treatment responses in patients with HIV-2, clinical assessment and CD4 count monitoring take on additional importance. Declining CD4 cell counts on ART would be consistent with virologic failure and risk of disease progression. Any evidence of thrush would also be an early clinical indicator of a failing regimen. New opportunistic infections or clinical AIDS-associated events may also occur in the first months after initiation of ART related to advanced AIDS. Clinical and laboratory monitoring every three to six months is advised based on stage of infection. (See
         <a class="medical medical_review" href="/z/d/html/3745.html" rel="external">
          "Primary care of adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2193912">
         <span class="h2">
          Adverse events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse events related to antiretroviral medications, and the type of monitoring needed for patients receiving ART, are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2196701">
         <span class="h1">
          PREVENTION AND TREATMENT OF OPPORTUNISTIC INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Until further data are available specifically for HIV-2, clinicians should follow guidelines for the prevention and treatment of opportunistic infections for HIV-1 [
         <a href="#rid125">
          125
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">
          "Overview of prevention of opportunistic infections in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2111303873">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">
          "Society guideline links: HIV treatment in nonpregnant adults and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H360298">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of therapy
         </strong>
         – Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in certain regions of the world where it is endemic, such as West Africa. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As in HIV-1 infection, the main goals of therapy are to attain viral suppression and improvement in CD4 cell counts, reduce mortality and morbidity, and reduce transmission to others. (See
         <a class="local">
          'Goals of therapy for HIV-2 infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indicators of immune function
         </strong>
         – The CD4 cell count is the main indicator of immune function in patients with HIV-2. Although patients with HIV-2 infection tend to have a slower immunologic decline than those with HIV-1, once the CD4 cell count is &lt;200 cells/microL, patients with HIV-2 are at high risk for morbidity and mortality from opportunistic infections, as seen in patients with HIV-1 infection. (See
         <a class="local">
          'Indicators of immune function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV-2 drug resistance
         </strong>
         – HIV-2 has intrinsic resistance to some entire classes of antiretroviral medications, such as the nonnucleoside reverse transcriptase inhibitors (NNRTIs) and the fusion inhibitors. Within the nucleoside reverse transcriptase inhibitor (NRTI) class, tenofovir appears to have the best drug resistance profile, while within the protease inhibitor (PI) class, lopinavir,
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9877" href="/z/d/drug information/9877.html" rel="external">
          saquinavir
         </a>
         have superior in vitro potency against HIV-2 compared with other PIs. Integrase strand transfer inhibitors have broad potent activity against HIV-2. (See
         <a class="local">
          'Classes of antiretroviral medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug resistance testing assays are not commercially available, which hampers the ability to check for resistance mutations prior to treatment initiation or during virologic failure on treatment. However, clinicians may obtain drug resistance testing from certain research facilities in the United States and Europe. (See
         <a class="local">
          'Assays for drug resistance testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to initiate antiretroviral therapy
         </strong>
         – Our approach to initiating antiretroviral therapy (ART) in patients with HIV- 2 is based in large part on data in patients with HIV-1 and vary to some extent based upon a patient's symptoms, risk for transmission, viral load, and CD4 count:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with HIV-2 infection who are symptomatic or have comorbidities that may improve with HIV therapy, we recommend initiation of ART (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For pregnant women and those who are in a discordant sexual partnership with an HIV-2-negative individual, we recommend initiation of ART to prevent transmission (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). Therapy should be initiated regardless of the CD4 count or viral load. (See
         <a class="local">
          'When to start antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For asymptomatic patients who have a detectable viral load and/or a CD4 count below the lower limit of normal (eg, &lt;750 cells/microL) we also suggest initiating ART (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, there are no data regarding the optimal time to initiate therapy in such patients. (See
         <a class="local">
          'When to start antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For asymptomatic patients who have an undetectable viral load and a normal CD4 count, a shared decision-making approach should be used to determine when antiretroviral therapy should be initiated. Such patients may never progress to AIDS or death, so the risks of taking ART must be weighed against the unknown benefits of improving clinical outcomes and preventing HIV-2 transmission. (See
         <a class="local">
          'When to start antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selecting an ART regimen
         </strong>
         – For treatment-naïve patients with HIV-2 infection, we suggest a three-drug combination therapy regimen with two nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). An alternative regimen should include two NRTIs plus a ritonavir-or cobicistat-boosted protease inhibitor active against HIV-2 (eg, lopinavir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         /ritonavir, or darunavir/
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ). The use of these regimens is based upon in vitro and observational data from small nonrandomized trials. (See
         <a class="local">
          'Selection of an initial antiretroviral regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient monitoring
         </strong>
         – Because HIV-2 viral load and resistance testing are often not available, patient monitoring is usually dependent on clinical symptomatology and CD4 count monitoring. Clinical and laboratory monitoring every three to six months is desirable depending on the stage of disease. (See
         <a class="local">
          'Patient monitoring'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacNeil A, Sarr AD, Sankalé JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esbjörnsson J, Månsson F, Kvist A, et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.
          </a>
         </li>
         <li class="breakAll">
          Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang M, Gottlieb GS, Dragavon JA, et al. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol 2012; 55:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Styer LM, Miller TT, Parker MM. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. J Clin Virol 2013; 58 Suppl 1:e127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bénard A, Damond F, Campa P, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS 2009; 23:1171.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1 (Accessed on September 30, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menéndez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 2014; 102:70.
          </a>
         </li>
         <li class="breakAll">
          Stanford University HIV Drug Resistance Database: HIV-2. https://hivdb.stanford.edu/hivdb/hiv2/by-sequences/ (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox SW, Apéria K, Albert J, Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 10:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damond F, Collin G, Matheron S, et al. Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir Ther 2005; 10:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer PL, Sarafianos SG, Clark PK, et al. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2:e10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Gottlieb GS, Anderson DJ, et al. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 2008; 52:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Anderson DJ, Pyrak CL, et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Badiane NM, Hawes SE, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009; 48:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS 2003; 17 Suppl 3:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodés B, Holguín A, Soriano V, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treviño A, de Mendoza C, Caballero E, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 2011; 66:1484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deuzing IP, Charpentier C, Wright DW, et al. Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses. J Virol 2015; 89:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Ende ME, Prins JM, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17 Suppl 3:S55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Ende ME, Guillon C, Boers PH, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raugi DN, Smith RA, Ba S, et al. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother 2013; 57:2751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodés B, Sheldon J, Toro C, et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masse S, Lu X, Dekhtyar T, et al. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother 2007; 51:3075.
          </a>
         </li>
         <li class="breakAll">
          Smith R, Ba S, Hawes S, et al. Toward Optimal ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug Resistance Testing Help Guide Therapy in HIV-2? In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colson P, Henry M, Tourres C, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pieniazek D, Rayfield M, Hu DJ, et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damond F, Brun-Vezinet F, Matheron S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodés B, Toro C, Sheldon JA, et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntemgwa M, Brenner BG, Oliveira M, et al. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007; 51:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raugi DN, Smith RA, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol 2015; 90:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schutten M, van der Ende ME, Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N Engl J Med 2000; 342:1758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Wu VH, Zavala CG, et al. In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu L, Anderson J, Ferns B, et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 2008; 24:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Raugi DN, Kiviat NB, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 2011; 25:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charpentier C, Larrouy L, Collin G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 2010; 24:2753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Raugi DN, Pan C, et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One 2012; 7:e45372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Raugi DN, Pan C, et al. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology 2015; 12:10.
          </a>
         </li>
         <li class="breakAll">
          Biktarvy package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf (Accessed on February 14, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Raugi DN, Wu VH, et al. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Smith RA, Dia Badiane NM, et al. HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. PLoS One 2011; 6:e22204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roquebert B, Blum L, Collin G, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 2008; 22:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni XJ, Delelis O, Charpentier C, et al. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology 2011; 8:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Hingrat Q, Collin G, Lê M, et al. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. Clin Infect Dis 2019; 69:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Wu VH, Song J, et al. Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants. J Infect Dis 2022; 226:497.
          </a>
         </li>
         <li class="breakAll">
          Armstrong-James D. Clinical outcome in a resistant HIV-2 infected man treated with raltegrevir and maraviroc: systemic response but failure to control viral replication in the brain. AIDS 2008 - XVII International AIDS Conference: Abstract no. TUPE0074
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willey S, Peters PJ, Sullivan WM, et al. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res 2005; 68:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espirito-Santo M, Santos-Costa Q, Calado M, et al. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors. AIDS Res Hum Retroviruses 2012; 28:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson K, Rowland-Jones S. Novel agents for the treatment of HIV-2 infection. Antivir Ther 2012; 17:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mörner A, Björndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sol N, Ferchal F, Braun J, et al. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J Virol 1997; 71:8237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaak H, Boers PH, Gruters RA, et al. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 2005; 79:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrego P, Calado R, Marcelino JM, et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther 2012; 17:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visseaux B, Hurtado-Nedelec M, Charpentier C, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis 2012; 205:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuaillon E, Gueudin M, Lemée V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37:1543.
          </a>
         </li>
         <li class="breakAll">
          Assessment report. Pifeltro. International non-proprietary name: doravirine. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/assessment-report/pifeltro-epar-public-assessment-report_en.pdf. (Accessed on January 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilleece Y, Chadwick DR, Breuer J, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010; 11:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347.
          </a>
         </li>
         <li class="breakAll">
          GlaxoSmithKline. Fostemsavir package insert. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/RUKOBIA/pdf/RUKOBIA-PI-PIL.PDF (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Hingrat Q, Collin G, Bachelard A, et al. Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates. AIDS 2022; 36:1055.
          </a>
         </li>
         <li class="breakAll">
          Lenacapavir Package Insert. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf. (Accessed on January 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu VH, Smith RA, Masoum S, et al. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Raugi DN, Nixon RS, et al. Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232. PLoS One 2023; 18:e0280568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berzow D, Descamps D, Obermeier M, et al. Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe. Clin Infect Dis 2021; 72:503.
          </a>
         </li>
         <li class="breakAll">
          French National AIDS Council. Medical care for people living with HIV: HIV-2 infection; Diversity of HIV-1. September 2016. https://cns.sante.fr/wp-content/uploads/2017/01/experts-vih_diversite.pdf (Accessed on July 15, 2020).
         </li>
         <li class="breakAll">
          World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. July 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1 (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matheron S, Damond F, Benard A, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drylewicz J, Eholie S, Maiga M, et al. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010; 24:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Loeff MF, Larke N, Kaye S, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson I, Togun O, de Silva T, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 2011; 25:2167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drylewicz J, Matheron S, Lazaro E, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ba S, Raugi DN, Smith RA, et al. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. Clin Infect Dis 2018; 67:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benard A, van Sighem A, Taieb A, et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis 2011; 52:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raugi DN, Ba S, Cisse O, et al. Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa. Clin Infect Dis 2021; 72:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Eholié SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069.
          </a>
         </li>
         <li class="breakAll">
          Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-2074. (Discussion)
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestre E, Ekouevi DK, Tchounga B, et al. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort. J Int AIDS Soc 2016; 19:20044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damond F, Lariven S, Roquebert B, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrett N, Xu L, Smit E, et al. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pujari S, Patel A, Gaikwad S, et al. Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. J Antimicrob Chemother 2020; 75:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delory T, Papot E, Rioux C, et al. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience. J Med Virol 2016; 88:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Descamps D, Peytavin G, Visseaux B, et al. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clin Infect Dis 2015; 60:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raugi DN, Diallo K, Diallo MB, et al. Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal. Trials 2021; 22:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matheron S, Descamps D, Gallien S, et al. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis 2018; 67:1161.
          </a>
         </li>
         <li class="breakAll">
          Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT03224338?cond=NCT03224338&amp;draw=2&amp;rank=1. (Accessed on January 27, 2023).
         </li>
         <li class="breakAll">
          First-Line Treatment for HIV-2 (FIT-2). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT02150993?cond=NCT02150993&amp;draw=2&amp;rank=1 (Accessed on January 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borget MY, Diallo K, Adje-Toure C, et al. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire. J Clin Virol 2009; 45:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landman R, Damond F, Gerbe J, et al. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodés B, Toro C, Jiménez V, Soriano V. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect Dis 2005; 41:e19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maniar JK, Damond F, Kamath RR, et al. Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma. Int J STD AIDS 2006; 17:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruelle J, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruelle J, Sanou M, Liu HF, et al. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses 2007; 23:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duarte F, Miranda AC, Peres S, et al. Transmitted drug resistance in drug-naïve HIV-2 infected patients. AIDS 2016; 30:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charpentier C, Visseaux B, Bénard A, et al. Transmitted drug resistance in French HIV-2-infected patients. AIDS 2013; 27:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzou PL, Descamps D, Rhee SY, et al. Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. J Infect Dis 2020; 221:1962.
          </a>
         </li>
         <li class="breakAll">
          HIV-2 EU GRADE Drug Resistance Database. http://www.hiv-grade.de/HIV2EU/deployed/grade.pl?program=hivalg (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on March 04, 2016).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16252 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7909009" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Slower heterosexual spread of HIV-2 than HIV-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8078737" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8040982" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8584359" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549974" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20804413" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19005275" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7904166" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cellular and plasma viral load in patients infected with HIV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7915856" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Reduced rate of disease development after HIV-2 infection as compared to HIV-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920314" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12590415" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17329334" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10479138" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093252" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255738" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30392769" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22820792" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22820792" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22832059" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24342472" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182471" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12126821" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19349850" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19349850" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345729" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345729" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15040537" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2334156" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7888232" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16312183" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16485036" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17967913" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358668" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19143530" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14565609" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10747109" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21558334" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Drug resistance mutations in patients infected with HIV-2 living in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25355888" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14565610" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11064499" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15332266" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16791023" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227188" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18312292" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23571535" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16464891" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576848" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576848" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14766818" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15090802" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635022" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327332" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17116674" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559830" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858105" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30012774" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : In Vitro Antiviral Activity of Cabotegravir against HIV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18718922" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18593344" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21971360" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20827161" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23028968" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25808007" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25808007" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30803972" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21765953" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18784469" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21854605" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30383215" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35134180" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35134180" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157392" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21902586" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22301192" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Novel agents for the treatment of HIV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9971817" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9343175" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15650194" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22293827" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Baseline susceptibility of primary HIV-2 to entry inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22140264" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15577405" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15577405" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21367732" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Update on human immunodeficiency virus (HIV)-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20961377" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16302461" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Enfuvirtide, the first fusion inhibitor to treat HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15117459" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Are fusion inhibitors active against all HIV variants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15117459" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Are fusion inhibitors active against all HIV variants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35262531" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35262531" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28559249" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36652466" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32227124" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32227124" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32227124" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16439883" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20397306" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20482865" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881480" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18301058" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29672676" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21507923" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33527119" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18832869" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18832869" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26861115" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18317013" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18520356" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Raltegravir treatment response in an HIV-2 infected patient: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32277827" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26636432" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25690598" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34922614" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590335" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590335" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29590335" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19375979" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19114866" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983906" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062187" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18304321" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17725411" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27243780" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Transmitted drug resistance in drug-naïve HIV-2 infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23595155" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Transmitted drug resistance in French HIV-2-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31965175" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31965175" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18434556" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813718" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
